Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BDTX Black Diamond Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: BDTX
Price (delayed)
$1.67
Market cap
$94.63M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.27
Enterprise value
$76.15M
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond
Highlights
Black Diamond Therapeutics's EPS has increased by 32% YoY and by 4.5% QoQ
The net income has grown by 15% YoY and by 4.7% from the previous quarter
The company's equity fell by 29% YoY and by 15% QoQ
The quick ratio has contracted by 28% YoY and by 12% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Key stats
What are the main financial stats of BDTX
Market
Valuations
Earnings
Shares outstanding
56.66M
Market cap
$94.63M
Enterprise value
$76.15M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.13
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$78.78M
Net income
-$69.68M
EBIT
-$69.68M
EBITDA
-$69.33M
Free cash flow
-$62.21M
Per share
Balance sheet
Liquidity
EPS
-$1.27
EPS diluted
-$1.27
Free cash flow per share
-$1.13
Book value per share
$1.47
Revenue per share
$0
TBVPS
$2.23
Total assets
$122.64M
Total liabilities
$39.36M
Debt
$18.78M
Equity
$83.29M
Working capital
$80.6M
Debt to equity
0.23
Current ratio
4.92
Quick ratio
4.83
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-50.4%
Return on equity
-70.4%
Return on invested capital
-64%
Return on capital employed
-68.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BDTX stock price
How has the Black Diamond Therapeutics stock price performed over time
Intraday
-1.18%
1 week
-6.18%
1 month
21.01%
1 year
-75.26%
YTD
-21.96%
QTD
7.74%
Financial performance
How have Black Diamond Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$78.78M
Net income
-$69.68M
Gross margin
N/A
Net margin
N/A
The net income has grown by 15% YoY and by 4.7% from the previous quarter
BDTX's operating income is up by 9% YoY and by 3.2% QoQ
Price vs fundamentals
How does BDTX's price correlate with its fundamentals
Growth
What is Black Diamond Therapeutics's growth rate over time
Valuation
What is Black Diamond Therapeutics stock price valuation
P/E
N/A
P/B
1.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Black Diamond Therapeutics's EPS has increased by 32% YoY and by 4.5% QoQ
The P/B is 48% lower than the last 4 quarters average of 2.2 and 36% lower than the 5-year quarterly average of 1.8
The company's equity fell by 29% YoY and by 15% QoQ
Efficiency
How efficient is Black Diamond Therapeutics business performance
BDTX's return on invested capital is up by 19% year-on-year
The ROA rose by 10% YoY
Black Diamond Therapeutics's ROE has increased by 8% YoY but it has decreased by 3.4% from the previous quarter
Dividends
What is BDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BDTX.
Financial health
How did Black Diamond Therapeutics financials performed over time
BDTX's current ratio is down by 28% year-on-year and by 11% since the previous quarter
The quick ratio has contracted by 28% YoY and by 12% from the previous quarter
The debt is 77% smaller than the equity
The company's equity fell by 29% YoY and by 15% QoQ
Black Diamond Therapeutics's debt to equity has increased by 21% YoY and by 15% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.